Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (10409)	7/2/1998 8:00:00 PM
From: AlienTech	Respond to of 23519

Biosonics Seeks FDA Approval for Alternative to Viagra FORT WASHINGTON, Penn.--(BW HealthWire)--June 30, 1998-- Biosonics, Inc. (OTC/BB: BISN) announced today that it is going forward with testing necessary in its efforts to obtain FDA marketing approval for MEGS(TM), a patented device which counteracts male impotence. BISN holds a design patent for MEGS(TM) (Male Electronic Genital Stimulator) -- a non-invasive alternative to Pfizer's (NYSE:PFE - news) Viagra and Vivus(TM) (NASDAQ:VVUS - news) Muse(TM). Based on the market demand for Pfizer's Viagra(TM), BISN has decided to proceed with its efforts to make MEGS commercially available. Jack Paller, Chief Executive Officer of BISN, explained the Company's decision, ''MEGS(TM) is a non-invasive, non-pharmaceutical means of addressing male impotence. Given the public demand for a solution to male impotence, going forward with our efforts to make MEGS(TM) publicly available at this time makes sense.'' BISN is involved in the development and marketing of electrotherapeutic and diagnostic devices to manage and treat several intractable medical conditions. To date, the Company holds six patents on its devices and has received FDA approval or clearance to market four of its products: Salitron(R) for dry mouth (competitor to MGI Pharmaceuticals' (NASDAQ:MOGN - news) product Saligen), Cystotron(TM) for urinary incontinence (competitor to EMPI Inc. (NASDAQ:EMPI - news) and Utah Medical), Anotron(TM) for fecal incontinence and the BIDDS(TM) glove which is a diagnostic tool. For additional information on BISN, please contact Raymond Bary of the NIBAR Group at 415/474-1647. vivus.com